Investment
Features
FeesSafety
Academy
More
Pluang+

Compare PDD Holdings Inc. American Depositary Shares (PDD) vs Sanofi SA (SNY) Price & Performance

PDD Holdings Inc. American Depositary SharesTrade

Price performance (Past 24H)

Key statistics

PDD Holdings Inc. American Depositary Shares vs Sanofi SA — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $79.19 (market cap $111.74B), while Sanofi SA trades at $40.1 (market cap $96.81B). The key difference: PDD Holdings Inc. American Depositary Shares is the larger of the two by market cap, and Sanofi SA pays a 6.02% dividend while PDD Holdings Inc. American Depositary Shares pays none. Which is the better fit depends on your goals.

PDDSNY
Market Cap
$111.74B$96.81B
Volume
4,029,8692,081,815
Sector
Consumer CyclicalHealth
52-Week High
$138.13$52.34
52-Week Low
$73.30$39.51
Enterprise Value
$44.39B$116.20B
Typical Hold Time
—94 Days
Dividend Yield
—6.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

PDD Holdings Inc. American Depositary Shares

No Aura AI signal available yet.

Sanofi SA

SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.

The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About PDD Holdings Inc. American Depositary Shares

PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.

Read more on PDD →

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY →